Oscar K Serrano1,2, Jonathan E Tannebaum3,4, Lindsay Cumella3,4, Jenny Choi3,4, Pratibha Vemulapalli3,4, W Scott Melvin3,4, Diego R Camacho3,4. 1. Montefiore Institute for Minimally Invasive Surgery, Montefiore Medical Center, Bronx, NY, USA. o.k.serrano@gmail.com. 2. Department of Surgery, Albert Einstein College of Medicine, 3400 Bainbridge Avenue, MAP 4., Bronx, NY, 104647, USA. o.k.serrano@gmail.com. 3. Montefiore Institute for Minimally Invasive Surgery, Montefiore Medical Center, Bronx, NY, USA. 4. Department of Surgery, Albert Einstein College of Medicine, 3400 Bainbridge Avenue, MAP 4., Bronx, NY, 104647, USA.
Abstract
BACKGROUND: Bariatric surgery has been established as the most effective long-term treatment for morbid obesity. METHODS: We performed a retrospective review of SSO patients treated at our institute between 2008 and 2013 who underwent a laparoscopic gastric bypass (LGBP) or sleeve gastrectomy (LSG). The primary end point for this study was excess weight loss (EWL) at 1, 3, 6, and 12 months. Secondary end points included procedure length (PL), length of stay (LOS), diabetes management and postoperative complications. RESULTS: We identified 135 SSO patients who underwent bariatric surgery (93 LGBP, 42 LSG) at our institute from 2008 to 2013 with a median follow-up of 49 months. The incidence of EWL > 30 % for patients in the LGBP group was 3.9, 29.0, 72.2 and 94.6 % at 1, 3, 6 and 12 months, respectively, while the incidence of EWL > 30 % in patients in the LSG group was 4.2, 25.0, 59.1 and 100 % at 1, 3, 6 and 12 months, respectively. PL was 124 ± 49 min for the LGBP group and 98 + 51 min for the LSG group (p < 0.005). LOS was on average 3.0 days (range 1-21) for the LGBP group and 3.4 days (range 1-13) for the LSG group (p = 0.41). Patients experienced a decrease in their hemoglobin A1C level by 10 % for the LGBP group and 9 % for the LSG group at 1 year (p = 0.89). Postoperative complications were seen in 15.1 % of LGBP patients and 4.8 % of LSG patients. CONCLUSIONS: Bariatric surgery is feasible in the SSO patients with comparable EWL outcomes and postoperative complications to historical non-SSO patients.
BACKGROUND: Bariatric surgery has been established as the most effective long-term treatment for morbid obesity. METHODS: We performed a retrospective review of SSO patients treated at our institute between 2008 and 2013 who underwent a laparoscopic gastric bypass (LGBP) or sleeve gastrectomy (LSG). The primary end point for this study was excess weight loss (EWL) at 1, 3, 6, and 12 months. Secondary end points included procedure length (PL), length of stay (LOS), diabetes management and postoperative complications. RESULTS: We identified 135 SSO patients who underwent bariatric surgery (93 LGBP, 42 LSG) at our institute from 2008 to 2013 with a median follow-up of 49 months. The incidence of EWL > 30 % for patients in the LGBP group was 3.9, 29.0, 72.2 and 94.6 % at 1, 3, 6 and 12 months, respectively, while the incidence of EWL > 30 % in patients in the LSG group was 4.2, 25.0, 59.1 and 100 % at 1, 3, 6 and 12 months, respectively. PL was 124 ± 49 min for the LGBP group and 98 + 51 min for the LSG group (p < 0.005). LOS was on average 3.0 days (range 1-21) for the LGBP group and 3.4 days (range 1-13) for the LSG group (p = 0.41). Patients experienced a decrease in their hemoglobin A1C level by 10 % for the LGBP group and 9 % for the LSG group at 1 year (p = 0.89). Postoperative complications were seen in 15.1 % of LGBP patients and 4.8 % of LSGpatients. CONCLUSIONS: Bariatric surgery is feasible in the SSO patients with comparable EWL outcomes and postoperative complications to historical non-SSO patients.
Entities:
Keywords:
Bariatric surgery; Excess weight loss; Laparoscopic Roux-en-Y gastric bypass; Laparoscopic sleeve gastrectomy; Super super obese
Authors: J Hunter Mehaffey; Damien J LaPar; Florence E Turrentine; Michael S Miller; Peter T Hallowell; Bruce D Schirmer Journal: Surg Obes Relat Dis Date: 2014-12-08 Impact factor: 4.734
Authors: D S Tichansky; E J DeMaria; A Z Fernandez; J M Kellum; L G Wolfe; J G Meador; H J Sugerman Journal: Surg Endosc Date: 2005-05-05 Impact factor: 4.584
Authors: Raquel Sánchez-Santos; Nuria Vilarrasa; Jorge Pujol; Pablo Moreno; Jose Manuel Francos; Antonio Rafecas; Carlos Masdevall Journal: Obes Surg Date: 2006-04 Impact factor: 4.129
Authors: Hassan Nasser; Tommy Ivanics; Oliver A Varban; Jonathan F Finks; Aaron Bonham; Amir A Ghaferi; Arthur M Carlin Journal: Surg Endosc Date: 2020-06-22 Impact factor: 4.584
Authors: Oscar K Serrano; Yang Zhang; Emily Kintzer; Erin Moran-Atkin; Jenny Choi; W Scott Melvin; Diego R Camacho Journal: Surg Endosc Date: 2016-03-11 Impact factor: 4.584
Authors: Adam C Celio; Qiang Wu; Kevin R Kasten; Mark L Manwaring; Walter J Pories; Konstantinos Spaniolas Journal: Surg Endosc Date: 2016-06-10 Impact factor: 4.584
Authors: Karl Rheinwalt; Tom F Ulmer; Sophia M-T Schmitz; Patrick H Alizai; Andreas Kroh; Sandra Schipper; Jonathan F Brozat; Andreas Plamper; Ulf P Neumann Journal: Surg Endosc Date: 2021-10-26 Impact factor: 3.453